Replies to post #13291 on BioCurex, Inc.(fka BOCX)

[quandongboy]

Everyone is buying the story that Abbott management were just too dumb to realize what they had with bocx. I don't buy that.

There are lots of technologies that work well in boutique labs, where each test can be given individual attention, but will not exhibit enough discrimination to run in mass / automated analyzers. An open question for me is whether that is the case with recaf. The scientific results for small samples (tens of tissue samples) are very encouraging, but will it still look as good when you test thousands of samples in an automated fashion?

Also, recaf is not the only horse / dog in town. There are a number of cancer biomarkers reaching the stage of clinical testing, and it is quite possible Abbott thought that these alternative markers were a better investment than recaf.

Some hard data on these questions would be welcome.

QB